{"name":"Elevar Therapeutics","slug":"elevar-therapeutics","ticker":"","exchange":"","domain":"elevar.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-01-30","type":"regulatory","source":"globenewswire.com","summary":"Elevar Therapeutics Announces FDA Acceptance of New Drug - globenewswire.com","headline":"Elevar Therapeutics Announces FDA Acceptance of New Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQT1dsLWZZeGdSUm5SVkJZQXRBOXp3ZXZLcDBCaG9nbWh0Z3puYm05N241WDJiemRKODZEZmpRbHhnZG1Bc3loT2QzRXhieTltRzkxOEZtYmVRTVFzdlBDZWlDYmtYRU8yZ01lRTd1N1ZzeHN2dEpVTC13ZVkxNm1aT1JwQXB5aERGOXVzWEZZeHpldXpUVWxrWjExbExaNGtaRGc?oc=5","date":"2026-01-30","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Cardiff churns C-suite to advance cancer candidate - Fierce Biotech","headline":"Chutes & Ladders—Cardiff churns C-suite to advance cancer candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPc1pjaFNNQU1iaW15aXl5Wk5yU3dRZWdHUDBsZFFVQlFVQXpQOG1pZFMyejh3aXZySGwtVmpfVm91WnhxbGEzVF9nWExuX3ZkbF9oaENndDA0bVprd0pQYktXSlJ6YmlCWXNzd0JMMFB4Ul9YMWlrTW1Zb3FMcGNmS0h1RnNsaDYwOXBudlpHaER3aTdlSFJwekYxdGtwbU82ZHhYWXVSWGQ1WFJ1bl94R2x5ZUU2Qm1SeEZla3VOUEhMb2o4dllEX3VOVFl3UmFzQkxvWlhGYWd2THZGdWdfckcyM3lTeFdScFlOQlJ4Q19lTll5cm9fSWJfQQ?oc=5","date":"2026-01-29","type":"pipeline","source":"globenewswire.com","summary":"Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy - globenewswire.com","headline":"Elevar Therapeutics Names Dong-Gun Kim CEO as It Focuses on Post-NDA Commercialization Strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPN1hQUEZISk0zXzF4Rk9NUTdUVUJJcTBpUWttQXBhSmZ0b3ZKdVMxZUNJdllhNEs1RDVFeE9lOE9oX1ZiSUlyaTljTjRqemphRVJFa1JjTVpWVlRreFdrNW12c0w4bGtGOHBvQ09TSEZ0RkFOcEZ4ZmQwNGRiNkhRMFBLSTczTlA0OENMV3hmZms3UzZoV1B0X012SC13bEp3QklR?oc=5","date":"2025-08-15","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Padcev's new breakthrough; China Alzheimer's drug's fate; Fosun's DPP1 deal - Fierce Pharma","headline":"Fierce Pharma Asia—Padcev's new breakthrough; China Alzheimer's drug's fate; Fosun's DPP1 deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBnT0Z4ZVh5RngtZFZoUjAzYUZOVmNnMjFqVl9IcWdiQ2Faa1VKTHR2Vi0tWDk3dkZTZVpELURWR2NLdnBubE9rcm9qVHlDSVdWMVZkNG9Ocw?oc=5","date":"2025-08-13","type":"pipeline","source":"The Korea Herald","summary":"HLB appoints Brian Kim as CEO of US subsidiary Elevar Therapeutics - The Korea Herald","headline":"HLB appoints Brian Kim as CEO of US subsidiary Elevar Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5GTHhiX3NjNnk2dU80ejNRTE1hMVZtZG1felBhYTBNSm9vV2xhZzhGdjl2U1Q0cmlqeFc1VnpkODNyaW8yM29XaXBXUmZTMkQxZTdnY1pmR1dzYzRw?oc=5","date":"2025-08-08","type":"pipeline","source":"EurekAlert!","summary":"Reducing the global burden of liver cancer: Recommendations from The Lancet commission - EurekAlert!","headline":"Reducing the global burden of liver cancer: Recommendations from The Lancet commission - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5sNXdNMXJTX215ZFhPZExSbF9ta294dFVXVUwtaHdoX0RjUE85WGdiZjQ1ZU5qNEUwSVNtbVlvM21HMGxiWHk2VWpwTGlYeG9UaWkw?oc=5","date":"2025-03-24","type":"regulatory","source":"FirstWord Pharma","summary":"Jiangsu Hengrui, Elevar hit with second FDA snub for liver cancer duo - FirstWord Pharma","headline":"Jiangsu Hengrui, Elevar hit with second FDA snub for liver cancer duo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQVHJ6OENrOWhKanJya2tIelhhd0o0TlYxeGlTTld5c2k3Q3NFUGRWQ09iLTNnd01IQnV3dlpJVzllanhtbUZNZ3pkdG5HdVE5OTR0UkJJcDJDNDR0SW1wel9KemNLbkNqZ0sxeEEzUzRObWVVcTg4dFE2UjNqYXo1aUlJTEJXQlFGZ2Fjc1hwRzZqcS1WWGwySDZ5XzZWY1k?oc=5","date":"2025-03-21","type":"regulatory","source":"Fierce Pharma","summary":"FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again - Fierce Pharma","headline":"FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNWFMwWGFGUzU4QlVwLTRsS2RnQ3BnYk9yNTI5S01URXlKalRwMTJuckxHenEzVkh2YXZScUJMRGp6M2dCM181SkhXTzBnMThiQUtMRWt4YnFnT3FZZDJqMzlZLTdlOFdENURPV2pnMmRXWjhVZ2R1UVBYeVhJQkt1ekEzVUI1RmVQOXVJYmM0ZXNoQnhoclMzTQ?oc=5","date":"2024-12-03","type":"pipeline","source":"Yahoo Finance","summary":"Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - Yahoo Finance","headline":"Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Dri","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOS3JnZzFSZzJSYl9MZnk5STZNYWIwakd4QTFIZWdJN1ZjR1B2OWhGQXZ1M0s3WnRlcE9vQVNKaUM2Z2JVUXZseXVGR2t2aElwWjZGMlY3cmk5QjRCS1g0ZXJwS1BsenVkbnU2TUVEbUNXX2dNSG9ueFFvZ3Q5TExEWERWZUlXTjZyRzR1cjUwQWt2MkhGMXVyTFFTbm4zVXVRalVERTBicEN0S3lweDdGd240LUdmWnEtSHVfel9UMmFfTEk?oc=5","date":"2023-10-24","type":"pipeline","source":"BioWorld News","summary":"Elevar shells out $600M for rights to Hengrui’s anti-PD-1 antibody outside China, Korea - BioWorld News","headline":"Elevar shells out $600M for rights to Hengrui’s anti-PD-1 antibody outside China, Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPY2hnc3JyWU1mLUV0dV9FZjhXU28zNFhHSGREdXg3SnNLQ2h6eFI0US1oRkhveV9FMmROQ1VfWm53cVZoT2k2QnB1WWFvRUVuM1RHX2hIdF8wRGdvc3lzRW1lUGxlNTdCbGU3SzlHSVloUVVUdElWN1BmX3djT2JMM1hHbVFYTEIwb01RX214aXJDaEU3SnI4dHNrTXpyeFpkeTBJ?oc=5","date":"2023-03-07","type":"earnings","source":"BioSpace","summary":"Elevar Therapeutics Debuts New Corporate Headquarters in Fort Lee, New Jersey - BioSpace","headline":"Elevar Therapeutics Debuts New Corporate Headquarters in Fort Lee, New Jersey","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOWXZCb2JnSDNndU10aEdkb01vUEtrRjEtMjJZVlRjdUFlZ2pKajNyVlBPaS1PNzVkdGpvblFJR1RNZmtKMWRYSWoxU0tOVnZoeWJGa2dLWi16Ml9icXVtWE9aWE5XVnMyTmZCb2NZWkZfNm1neGFTbUEwa1VscHgwV1NUTmVtOHVNMGlkRi1KckpQTFNVYzBTQWsyZEttVTJQb3JpNnBUQnFGbGZOY3BZa1NtV1NjSjJGX2dIOEplcllqNHl4LUJMVHVCTmZ4bmx0XzlidTloTmpHLUkzV3BhMUlTb0hmVkRCMnRkZDVnbUNhRHpDS25INF8xaUloOEdiM0FMdWhZb2lwUWQwaFNTZ3o3dlZ0RGpYNjl1YS1xNFR3QQ?oc=5","date":"2020-12-01","type":"pipeline","source":"PR Newswire","summary":"Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea® (paclitaxel micellar) - PR Newswire","headline":"Elevar Therapeutics and Tanner Pharma Group Announce Launch of Global Named Patient Program to Provide Access to Apealea","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}